Drugs / AP601
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07165067 | Jan 2026 → Dec 2027 expected | cancer | AP Biosciences Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07165067 ↗ |
| Route | Intravenous | “All doses of AP601 will be admistered intraveneously.” NCT07165067 ↗ |